Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study
Mehmet TasdemirNur CanpolatNurdan YıldızGul OzcelikMeryem BenzerSeha Kamil SaygiliEmine Neşe ÖzkayinÖzde Nisa TürkkanAyse BalatCengiz CandanMehtap ÇelakılSevgi YavuzNurver AkıncıNilüfer GöknarCihangir AkgünSebahat TülparHarika AlpayFatma Lale SeverIlmay BilgePublished in: Turkish journal of medical sciences (2021)
The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.